Vibeke Maniche

Dr. Vibeke Maniche


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2024 in Medicina
Verified
Journal Article
Open access
PDF file
VMVibeke Maniche
Vibeke Maniche
MSMax Schmeling
Max Schmeling
JGJonathan Gilthorpe
Jonathan Gilthorpe
PHPeter Riis Hansen
Peter Riis Hansen
Background and Objective: An unexpected batch-dependent safety signal for the BNT162b2 mRNA COVID-19 vaccine was recently identified in a nationwide study from Denmark, but the generalizability of this finding is unknown. Therefore, we compared batch-dependent rates of suspected adverse events (SAEs) reported to national authorities in Denmark and Sweden. Materials and Methods: SAE and vaccine batch data were received from national authorities in Denmark and Sweden, and analyses of heterogeneity in the relationship between numbers of vaccine doses and SAEs per batch were performed, along with comparison of SAE rates and severities for batches that were shared between the two countries. Results: Significant batch-dependent heterogeneity was found in the number of SAEs per 1000 doses for both countries, with batches associated with high SAE rates detected in the early phase of the vaccination campaign and positive correlations observed between the two countries for the severity of SAEs from vaccine batches that they shared. Mild SAEs predominated in the batches used in the early part of the vaccination roll-out, where markedly higher SAE rates per 1000 doses in Denmark for the batches that were shared between the two countries suggested that a large proportion of these SAEs were under-reported in Sweden. Conclusions: The batch-dependent safety signal observed in Denmark and now confirmed in Sweden suggests that early commercial batches of BNT162b2 may have differed from those used later on, and these preliminary and hypothesis-generating results warrant further study.

19 June 2025 in International Journal of Risk & Safety in Medicine
Verified
Journal Article
Open access
VMVibeke Maniche
Vibeke Maniche
TFTomáš Fürst
Tomáš Fürst
MSMax Schmeling
Max Schmeling
JGJonathan Gilthorpe
Jonathan Gilthorpe
PHPeter Riis Hansen
Peter Riis Hansen
Background: Adverse effects of COVID-19 vaccination on human menstrual cycle characteristics have been observed, but limited data are available on the relationship between COVID-19 vaccination status and birth rates. Objectives: Therefore, we used nationwide data from the Czech Republic to examine rates of successful conceptions (SCs), that is, conceptions leading to live births 9 months later, for women who were either vaccinated or unvaccinated against COVID-19 before SC. Methods: Summary monthly COVID-19 vaccination and birth data for women in the Czech Republic aged 18–39 years were retrieved for the period from January 2021 to December 2023. The numbers of SCs per month per 1000 women were calculated for preconception-vaccinated or unvaccinated women, respectively, as well as the number of SCs per month per 1000 women for all women aged 18–39 years. Results: During the study period, there were approximately 1,300,000 women aged 18–39 years in the Czech Republic, and the proportion of COVID-19-vaccinated women increased from January 2021 until reaching a steady state of around 70% by the end of 2021. At least from June 2021, SCs per 1000 women were considerably lower for women who were vaccinated, compared to those that were unvaccinated, before SC. Furthermore, SC rates for the vaccinated group were much lower than expected based on their proportion of the total population. Conclusions: In the Czech Republic, SC rates were substantially lower for women vaccinated against COVID-19 before SC than for those who were not vaccinated. These hypothesis-generating and preliminary results call for further studies of the potential influence of COVID-19 vaccination on human fecundability and fertility.

27 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MSMax Schmeling
Max Schmeling
TFTomáš Fürst
Tomáš Fürst
VMVibeke Maniche
Vibeke Maniche
PHPeter Riis Hansen
Peter Riis Hansen
JGJonathan Gilthorpe
Jonathan Gilthorpe
Background: Variation in suspected adverse drug reactions (SARs) linked to different batches of COVID-19 vaccines has been reported in several countries, including the Czech Republic, Denmark, Sweden, and the USA. However, SAR data from spontaneous reporting systems are subject to under-reporting and other biases. To investigate the potential association between vaccine batches and adverse reactions using an unequivocal endpoint, we examined the temporal relationship between all-cause mortality (ACM) and COVID-19 vaccine type and batch up to three months after vaccination.Methods: We analysed nationwide data from the Czech Republic on vaccine type and batch, together with corresponding three-month ACM data. Cluster analysis was used to assess age- and sex-specific differences in ACM within and across vaccine batches and types. We also investigated the relationship between ACM and SAR rates for the same batches.Results: During a 21-month period (December 2020 to September 2022), vaccine batches clustered according to their three-month age- and sex-adjusted ACM rates for the four products administered (Comirnaty, Spikevax, Vaxzevria, and Jcovden). For Comirnaty, Spikevax, and Vaxzevria, a clear temporal pattern was observed, with earlier batches showing significantly higher ACM rates. A strong correlation was found between batches that clustered by ACM and those previously identified as clustering by SARs, across all vaccine products except Jcovden.Conclusions: Data from the Czech Republic show a clear association between administered COVID-19 vaccine batches and 3-month ACM rates for Comirnaty, Spikevax, and Vaxzevria, with earlier batches linked to notably higher ACM. A strong correlation between batch-associated ACM and SAR rates for Comirnaty and Spikevax supports the validity of these batch-related safety signals and warrants further investigation using individual-level patient data.

7 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
VMVibeke Maniche
Vibeke Maniche
TFTomáš Fürst
Tomáš Fürst
MSMax Schmeling
Max Schmeling
JGJonathan Gilthorpe
Jonathan Gilthorpe
PHPeter Riis Hansen
Peter Riis Hansen
Background/objectives: Adverse effects of COVID-19 vaccination on human menstrual cycle characteristics have been observed, but limited data are available on the relationship between COVID-19 vaccination status and birth rates. Therefore, we used nationwide data from the Czech Republic to examine rates of successful conceptions (SCs), i.e., conceptions leading to live births 9 months later, for women who were either vaccinated or unvaccinated against COVID-19 before SC. Methods: Summary monthly COVID-19 vaccination and birth data for women in the Czech Republic aged 18-39 years were retrieved for the period from January 2021 to December 2023. The numbers of SCs per month per 1,000 women were calculated for preconception-vaccinated or unvaccinated women, respectively, as well as the number of SCs per month per 1,000 women for all women aged 18-39 years. Results: During the study period, there were approximately 1,300,000 women aged 18-39 years in the Czech Republic, and the proportion of COVID-19-vaccinated women increased from January 2021 until reaching a steady state of around 70% by the end of 2021. At least from June 2021, SCs per 1,000 women were considerably lower for women who were vaccinated, compared to those that were unvaccinated, before SC. Furthermore, SC rates for the vaccinated group were much lower than expected based on their proportion of the total population. Conclusions: In the Czech Republic, SC rates were substantially lower for women vaccinated against COVID-19 before SC than for those who were not vaccinated. These hypothesis-generating and preliminary results call for further studies of the potential influence of COVID-19 vaccination on human fecundability and fertility.

10 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
VMVibeke Maniche
Vibeke Maniche
VKVít Karásek
Vít Karásek
MSMax Schmeling
Max Schmeling
JGJonathan D. Gilthorpe
Jonathan D. Gilthorpe
TFTomáš Fürst
Tomáš Fürst
PHPeter Riis Hansen
Peter Riis Hansen
Background: Preliminary reports have suggested a batch-dependent safety signal for COVID-19 vaccines. It is important to establish if these findings can be replicated. Methods: We used publicly available nationwide data from Germany spanning the first 3.5 years of the vaccination campaign to calculate weekly rates of spontaneously reported suspected adverse events (SAEs) per 1 000 administered vaccine doses. Results: SAE rates ranged between 2.2 and 22.8 per 1 000 doses and women accounted for 72% of all SAEs. Crucially, SAE rates for Comirnaty (Pfizer-BioNTech), Spikevax (Moderna), and Vaxzevria (AstraZeneca) were very high in the initial phase of vaccination rollout and hereafter declined precipitously. For example, SAE rates in weeks 1-4 of 2021 were 8.2, 50.8, and 620.9 per 1 000 doses of Comirnaty, Spikevax, and Vaxzevria, respectively, but fell to 4.4, 11.6, and 7.4 per 1 000 doses in weeks 12-16 of 2021. Conclusions: SAE rates in Germany were highly elevated in the initial phase of COVID-19 vaccination rollout and then fell precipitously, a pattern compatible with a batch-dependent safety signal. Furthermore, there was a considerable overrepresentation of women with SAEs. These preliminary results call for more definitive studies of batch-dependent COVID-19 vaccine safety.